{"id":33257,"date":"2018-02-14T12:00:00","date_gmt":"2018-02-14T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/"},"modified":"2018-02-14T12:00:00","modified_gmt":"2018-02-14T12:00:00","slug":"inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/","title":{"rendered":"Inmunoterapia con al\u00e9rgenos: desaf\u00edos para la prevenci\u00f3n del asma"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1493 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Debates Futuros en Rinolog\u00eda Bruselas 2017<\/h2>\n<p>Los expertos recomiendan que los ni\u00f1os a partir de los cinco a\u00f1os reciban inmunoterapia con al\u00e9rgenos si tienen predisposici\u00f3n familiar. Estos ni\u00f1os constituyen la poblaci\u00f3n diana ideal para la inmunoterapia con al\u00e9rgenos. Los candidatos ideales son aquellos con rinitis al\u00e9rgica pero sin asma; no obstante, con alg\u00fan indicio de que la rinitis al\u00e9rgica probablemente se extienda a las v\u00edas respiratorias inferiores. Este indicio podr\u00eda ser hiperreactividad bronquial o el hecho de que presenten sibilancias con los resfriados o que su eosinofilia nasal se eleve durante la temporada de fiebre del heno.   <\/p>\n<p>Las entrevistas se grabaron durante el Rhinology Future Debates Bruselas 2017 con Oliver Pfaar, David Price y Glenis Scadding.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1494 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\"><center><iframe title=\"Reproductor de v\u00eddeo de YouTube\" src=\"https:\/\/www.youtube.com\/embed\/G1VWFi6Lq84?rel=0\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/center><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Debates Futuros en Rinolog\u00eda Bruselas 2017 Los expertos recomiendan que los ni\u00f1os a partir de los cinco a\u00f1os reciban inmunoterapia con al\u00e9rgenos si tienen predisposici\u00f3n familiar. Estos ni\u00f1os constituyen la poblaci\u00f3n diana ideal para la inmunoterapia con al\u00e9rgenos. Los candidatos ideales son aquellos con rinitis al\u00e9rgica pero sin asma; no obstante, con alg\u00fan indicio de que la rinitis al\u00e9rgica probablemente se extienda a las v\u00edas respiratorias inferiores. Este indicio podr\u00eda ser hiperreactividad bronquial o el hecho de que presenten sibilancias con los resfriados o que su eosinofilia nasal se eleve durante la temporada de fiebre del heno. Las entrevistas se grabaron durante el Rhinology Future Debates Bruselas 2017 con Oliver Pfaar, David Price y Glenis Scadding.<\/p>\n","protected":false},"author":1,"featured_media":33271,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[202],"tags":[253,176,177,203,205,206],"class_list":["post-33257","news","type-news","status-publish","has-post-thumbnail","hentry","category-debates-futuros-de-rinologia","tag-inmunoterapia-con-alergenos-ait","tag-profesionales-sanitarios","tag-asma","tag-rinologia","tag-debates","tag-debates-futuros-de-rinologia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Inmunoterapia con al\u00e9rgenos: desaf\u00edos para la prevenci\u00f3n del asma - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inmunoterapia con al\u00e9rgenos: desaf\u00edos para la prevenci\u00f3n del asma\" \/>\n<meta property=\"og:description\" content=\"Debates Futuros en Rinolog\u00eda Bruselas 2017 Los expertos recomiendan que los ni\u00f1os a partir de los cinco a\u00f1os reciban inmunoterapia con al\u00e9rgenos si tienen predisposici\u00f3n familiar. Estos ni\u00f1os constituyen la poblaci\u00f3n diana ideal para la inmunoterapia con al\u00e9rgenos. Los candidatos ideales son aquellos con rinitis al\u00e9rgica pero sin asma; no obstante, con alg\u00fan indicio de que la rinitis al\u00e9rgica probablemente se extienda a las v\u00edas respiratorias inferiores. Este indicio podr\u00eda ser hiperreactividad bronquial o el hecho de que presenten sibilancias con los resfriados o que su eosinofilia nasal se eleve durante la temporada de fiebre del heno. Las entrevistas se grabaron durante el Rhinology Future Debates Bruselas 2017 con Oliver Pfaar, David Price y Glenis Scadding.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\\\/\",\"name\":\"Inmunoterapia con al\u00e9rgenos: desaf\u00edos para la prevenci\u00f3n del asma - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Allergen20immunotherapy_Challenges20for20the20prevention20of20asthma.png\",\"datePublished\":\"2018-02-14T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\\\/#breadcrumb\"},\"inLanguage\":\"es-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Allergen20immunotherapy_Challenges20for20the20prevention20of20asthma.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Allergen20immunotherapy_Challenges20for20the20prevention20of20asthma.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/elige-tu-camino\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Inmunoterapia con al\u00e9rgenos: desaf\u00edos para la prevenci\u00f3n del asma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Inmunoterapia con al\u00e9rgenos: desaf\u00edos para la prevenci\u00f3n del asma - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/","og_locale":"es_ES","og_type":"article","og_title":"Inmunoterapia con al\u00e9rgenos: desaf\u00edos para la prevenci\u00f3n del asma","og_description":"Debates Futuros en Rinolog\u00eda Bruselas 2017 Los expertos recomiendan que los ni\u00f1os a partir de los cinco a\u00f1os reciban inmunoterapia con al\u00e9rgenos si tienen predisposici\u00f3n familiar. Estos ni\u00f1os constituyen la poblaci\u00f3n diana ideal para la inmunoterapia con al\u00e9rgenos. Los candidatos ideales son aquellos con rinitis al\u00e9rgica pero sin asma; no obstante, con alg\u00fan indicio de que la rinitis al\u00e9rgica probablemente se extienda a las v\u00edas respiratorias inferiores. Este indicio podr\u00eda ser hiperreactividad bronquial o el hecho de que presenten sibilancias con los resfriados o que su eosinofilia nasal se eleve durante la temporada de fiebre del heno. Las entrevistas se grabaron durante el Rhinology Future Debates Bruselas 2017 con Oliver Pfaar, David Price y Glenis Scadding.","og_url":"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/","url":"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/","name":"Inmunoterapia con al\u00e9rgenos: desaf\u00edos para la prevenci\u00f3n del asma - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Allergen20immunotherapy_Challenges20for20the20prevention20of20asthma.png","datePublished":"2018-02-14T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/#breadcrumb"},"inLanguage":"es-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/"]}]},{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Allergen20immunotherapy_Challenges20for20the20prevention20of20asthma.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Allergen20immunotherapy_Challenges20for20the20prevention20of20asthma.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/es\/news\/inmunoterapia-con-alergenos-desafios-para-la-prevencion-del-asma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.euforea.org\/es\/elige-tu-camino\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/es\/news\/"},{"@type":"ListItem","position":3,"name":"Inmunoterapia con al\u00e9rgenos: desaf\u00edos para la prevenci\u00f3n del asma"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/es\/#website","url":"https:\/\/www.euforea.org\/es\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-ES"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/es\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.euforea.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/33257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/comments?post=33257"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/33257\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/media\/33271"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/media?parent=33257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/categories?post=33257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/tags?post=33257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}